MBX Biosciences (MBX) Interest Coverage Ratio (2023 - 2026)
MBX Biosciences (MBX) posted Interest Coverage Ratio of 0.35 for Q1 2026, up 99.87% sequentially from 257.95 in Q4 2025, and up 95.87% YoY from 0.18 in Q1 2025.
MBX Biosciences (MBX) Interest Coverage Ratio (2023 - 2026) Analysis & Trends
MBX Biosciences has reported Interest Coverage Ratio for 4 years, with the latest figure at 0.35 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 95.87% year-over-year to 0.35 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.26 (up 95.12% YoY) and the FY2025 annual result came in at 1.0, up 39.02% from the prior year.
- Interest Coverage Ratio climbed to 0.35 in Q1 2026 per MBX's latest filing, from 257.95 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.35 in Q1 2026 and troughed at 257.95 in Q4 2025.
- A 4-year average of 84.11 and a median of 8.4 in 2025 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2024 and 2025: Interest Coverage Ratio plunged 8362.14% in 2024, then surged 98.99% in 2025.
- Over 4 years, Interest Coverage Ratio stood at 2.2 in 2023, then slumped by 8362.14% to 186.1 in 2024, then plunged by 38.61% to 257.95 in 2025, then surged by 99.87% to 0.35 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 0.35, 257.95, and 0.63 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | MBX Biosciences | 3.29 Bn | 3.29 Bn | - | -0.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.22 |
| Mar 31, 2026 | -0.35 |
| Dec 31, 2025 | -257.95 |
| Sep 30, 2025 | -0.63 |
| Jun 30, 2025 | -1.69 |
| Mar 31, 2025 | -8.40 |
| Dec 31, 2024 | -186.10 |
| Jun 30, 2024 | -166.58 |
| Mar 31, 2024 | -133.14 |
| Dec 31, 2023 | -2.20 |